← All indications
Esophagitis
INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.
Subtype terms (2)
More specific conditions that are subtypes of Esophagitis in the MeSH hierarchy.
- Eosinophilic Esophagitis
46 drugs (30 approved, 16 experimental)
- Esophagitis, Peptic
14 drugs (8 approved, 6 experimental)
Drugs by status
Approved for this indication (7)
Phase 4 trials (4)
Phase 3 trials (8)
Phase 2 trials (14)
Phase 1 trials (2)
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (29)
- Bausch Health Companies
- TAP Pharmaceuticals
- Wyeth
- Parexel
- Chong Kun Dang Pharmaceutical
- Otsuka
- United States Army
- University of Roma La Sapienza
- Severance Hospital
- Chang Gung University
- Emory University
- National Cheng Kung University
- Shaanxi Provincial People's Hospital
- University of Tennessee
- Yonsei University
- Mayo Clinic
- University of Colorado, Denver
- Konyang University
- Janssen Pharmaceutica NV
- Soonchunhyang University
- Kyungpook University
- Department of Veteran Affairs
- University of Colorado
- Ankang City Central Hospital
- Baoji Central Hospital
- Hanzhong Central Hospital
- Chonnam National University
- Johnson and Johnson
- People's Liberation Army of China
Organization Involved with Phase 3 Indications (43)
- PPD
- Ception
- Meda
- Regeneron
- Eisai
- Cephalon
- Shire
- Pfizer
- Sanofi
- Allakos, Inc.
- Healios K.K.
- Il-Yang Pharm. Co., Ltd.
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
- Yooyoung Pharmaceutical Co.,Ltd.
- Daewoong Pharmaceutical Co. LTD.
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Dr. Falk Pharma GmbH
- Cancer Research Network
- Changhai Hospital
- Gottfried Wilhelm Leibniz Universität Hannover
- Hanyang University
- Hoosier Cancer Research Network
- Juntendo University
- Korea University
- Medical College of Wisconsin
- Seoul National University
- Tohoku University
- University of Cincinnati
- +13 more
Organization Involved with Phase 2 Indications (49)
- Zeria Pharmaceutical
- Meritage Pharma
- Celgene
- Forest Laboratories
- MedImmune
- Novartis
- Arena Pharmaceuticals
- DBV Technologies
- GlaxoSmithKline
- Oxagen Ltd
- Steba Biotech S.A.
- National Cancer Institute (NCI)
- Vastra Gotaland Region
- University of Pennsylvania
- University of Arizona
- Baylor University
- Harvard University
- Indiana University
- NRG Oncology
- Northwestern University
- Ohio State University
- Radiation Therapy Oncology Group
- Rhode Island Hospital
- Swiss EE Study Group
- Tufts University
- University of Iowa
- University of South Florida
- University of Alberta
- University of Bern
- University of California, Irvine
- +19 more
Organization Involved with Phase 1 Indications (13)
Organization Involved with Other Experimental Indications (9)